SLC5A2 and familial dilated cardiomyopathy: Only a few studies with limited patient numbers have assessed the role of SGLT2 inhibitors in patients with DCM and NIDCM.[13] The purpose of this study was to further explore the effect of the combined use of SGLT2 inhibitors on cardiac structure and systolic function in patients with newly diagnosed NIDCM treated with conventional therapy.